Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $18.79 (market cap $8.59B), while Regeneron Pharmaceuticals Inc trades at $790.11 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 9.6× Norwegian Cruise Line Holdings Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| NCLH | REGN | |
|---|---|---|
Market Cap | $8.59B | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $812.27 |
52-Week Low | $14.79 | $555.51 |
Enterprise Value | $23.40B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $18.55, down 3.64% today, amid a bearish technical signal. The company reported Q2 2026 EPS of $0.48, beating estimates, but faces headwinds from high fuel costs and soft demand. Revenue growth is steady, with 2025 revenue at $9.83B, and profitability metrics like a 7.49% net income margin show resilience. Analyst consensus is bullish with a $20.73 price target, though recent news highlights execution risks and macroeconomic pressures.
The outlook is mixed: strong fundamentals and analyst support suggest upside potential, but near-term volatility from cost pressures and travel demand uncertainty poses risks. Investors should weigh the attractive valuation against operational challenges in the cruise industry.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
